CoChat

The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers

Open access
Drew, Yvette, Calvert, Hilary · 2008 · Annals of the New York Academy of Sciences
Cited by 61

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

The abundant nuclear enzyme poly(ADP‐ribose) polymerase‐1 (PARP‐1), represents an important novel target in cancer therapy. PARP‐1 is essential to the repair of DNA single‐strand breaks via the base excision repair pathway. Inhibitors of PARP‐1 have been shown to enhance the cytotoxic effects of ionizing radiation and DNA damaging chemotherapy agents, such as the methylating agents and topoisomerase I inhibitors. There are currently at least five PARP inhibitors in clinical trial development. Recent in vitro and in vivo evidence suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer associated (BRCA) 1 and 2 genes. This theory of selectively exploiting cells defective in one DNA repair pathway by inhibiting another is a major breakthrough in the treatment of cancer. BRCA1/2 mutations are responsible for the majority of genetic breast/ovarian cancers, known as the hereditary breast ovarian cancer syndrome. This review summarizes the preclinical and clinical evidence for the potential of PARP inhibitors in genetic breast and ovarian cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1196/annals.1414.020

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 45

  1. 10.1001/jama.279.12.922 · DOI · Paper page
  2. Kerlikowske K., 1992, Should women with familial ovarian cancer undergo prophylactic oophorectomy?, Obstet. Gynecol., 80, 700
  3. 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B · DOI · Paper page
  4. 10.1056/NEJM199704173361602 · DOI · Paper page
  5. 10.1086/421251 · DOI · Paper page
  6. 10.1126/science.1978757 · DOI · Paper page
  7. 10.1086/301639 · DOI · Paper page
  8. 10.1038/ng1837 · DOI · Paper page
  9. 10.1053/gast.2000.20228 · DOI · Paper page
  10. 10.1093/carcin/bgl062 · DOI
  11. 10.1002/ijc.2910640613 · DOI · Paper page
  12. 10.1093/jnci/94.18.1365 · DOI · Paper page
  13. 10.1093/jnci/91.15.1310 · DOI · Paper page
  14. 10.1200/JCO.2004.05.055 · DOI · Paper page
  15. 10.1093/jnci/djj465 · DOI · Paper page
  16. Levy‐Lahad E., 1997, Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast‐ovarian cancer families, Am. J. Hum. Genet., 60, 1059
  17. 10.1073/pnas.68.4.820 · DOI · Paper page
  18. 10.1126/science.7545954 · DOI · Paper page
  19. 10.1038/378789a0 · DOI · Paper page
  20. 10.1038/sj.onc.1209874 · DOI · Paper page
  21. 10.1038/nrg1746 · DOI · Paper page
  22. 10.1016/S1097-2765(02)00580-4 · DOI
  23. 10.1016/S1097-2765(01)00175-7 · DOI · Paper page
  24. 10.1016/S0092-8674(01)00209-4 · DOI
  25. 10.1038/sj.onc.1209881 · DOI
  26. 10.1074/jbc.C000276200 · DOI · Paper page
  27. 10.1038/sj.bjc.6600859 · DOI · Paper page
  28. 10.1038/nrm1963 · DOI · Paper page
  29. 10.1007/BF00928449 · doi:10.1007/bf00928449
  30. 10.1111/j.1469-185X.1990.tb01240.x · doi:10.1111/j.1469-185x.1990.tb01240.x
  31. 10.1093/nar/gkg703 · DOI · Paper page
  32. 10.1093/nar/gkl108 · DOI · Paper page
  33. 10.1101/gad.1331805 · DOI · Paper page
  34. 10.1042/bj1850775 · DOI · Paper page
  35. 10.1126/science.6420886 · DOI · Paper page
  36. Plummer R., 2005, First in human phase I trial of the PARP inhibitor AG‐014699 with Temozolomide (TMZ) in patients (pts) with advanced solid tumours, Proc. Am. Soc. Clin. Oncol., 10.1200/jco.2005.23.16_suppl.3065 · DOI
  37. Plummer R., 2006, First and final report of a phase II study of the poly(ADP‐ribose) polymerase (PARP) inhibitor, AG014699, in combination with Temozolomide (TMZ) in patients with metastatic malignant melanoma (MM), Proc. Am. Soc. Clin. Oncol., 10.1200/jco.2006.24.18_suppl.8013 · DOI · Paper page
  38. Yap T.A., 2007, First in human phase 1 pharmacokinetic and pharmacodynamic study of KU‐0059436 (Ku), a small molecule inhibitor of Poly(ADP‐ribose) polymerase (PARP) in cancer patients including BRCA1/2 mutation carriers, Proc. Am. Soc. Clin. Oncol.
  39. Kummar S., 2007, Inhibition of poly (ADP‐ribose) polymerase (PARP) by ABT‐888 in patients with advanced malignancies: results of a phase 0 trial, J. Clin. Oncol., 25, 3518, 10.1200/jco.2007.25.18_suppl.3518 · doi:10.1200/jco.2007.25.18_suppl.3518
  40. 10.1038/nature03443 · DOI · Paper page
  41. 10.1038/nature03445 · DOI · Paper page
  42. 10.1038/nrg816 · DOI · Paper page
  43. Baldwin R.L., 2000, BRCA1 promoter region hypermethylation in ovarian carcinoma: a population‐based study, Cancer Res., 60, 5329
  44. 10.1016/S0092-8674(03)00930-9 · DOI · Paper page
  45. 10.1200/JCO.2005.05.4171 · DOI · Paper page

Cited by

See all 61

Metadata

Authors
Drew, Y., & Calvert, H.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2008-09
Volume
1138
Issue
1
Pages
136-145
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W1976583784
Cited by
61
References
7
FWCI
5.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers. https://app.cochat.ai/papers/10.1196/annals.1414.020
The paper
Drew, Y., & Calvert, H. (2008). The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1414.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.